Recent News

• 05.22.2025 - Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
• 05.22.2025 - Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
• 05.20.2025 - Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
• 05.20.2025 - Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
• 05.14.2025 - Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
• 05.14.2025 - Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
• 05.13.2025 - Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
• 05.13.2025 - Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
• 05.06.2025 - Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
• 05.06.2025 - Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Recent Filings

• 05.21.2025 - EX-99.1 EX-99.1
• 05.21.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2025 - 8-K Current report